Form 4 GeneDx Holdings Corp For: 9 March
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GeneDx Holdings Corp (WGS)
GeneDx Holdings Corp stock price, this page displays NASDAQ WGS stock exchange data. View the WGS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the GeneDx Holdings Corp real time stock price chart below.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the WGS quote. (ISIN: US81663L2007)
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the WGS quote. (ISIN: US81663L2007)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.00
95.38
52 wk Range
55.17
170.87
WGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.0095.38
52 wk Range
55.17170.87
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
WGS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
156.67
Upside
+65.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Form 4 GeneDx Holdings Corp For: 5 March
- Investing.com
- Form 4 GeneDx Holdings Corp For: 9 March
- Investing.com
- Form 4 GeneDx Holdings Corp For: 5 March
- Investing.com
- GeneDx CFO Feeley sells $486k in shares
- Investing.com
- CM Life Sciences receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
GeneDx Holdings Corp Earnings Call Summary for Q3/2025
- GeneDx reported Q3 2025 EPS of -$0.27, missing forecast by 165.85%, while revenue beat expectations at $116.7 million, up 52% YoY
- Stock fell 2.04% in pre-market trading despite revenue beat; company raised full-year guidance to $425-$428 million
- Exome and genome revenues grew 66% YoY to $98.9 million; company holds 80% market share in U.S. clinical exome and genome testing
- GeneDx targets 30% increase in testing volume, expanding into general pediatrician and NICU markets
- Analysts maintain strong buy consensus; company expects continued growth despite operational challenges impacting profitability
Last Updated: 28-10-2025, 08:00 pm
Read Full TranscriptCompare WGS to Peers and Sector
Metrics to compare | WGS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWGSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −131.7x | 27.4x | −0.5x | |
PEG Ratio | −2.12 | 1.25 | 0.00 | |
Price/Book | 9.0x | 2.5x | 2.6x | |
Price / LTM Sales | 6.5x | 1.6x | 3.2x | |
Upside (Analyst Target) | 63.9% | 43.8% | 51.4% | |
Fair Value Upside | Unlock | 11.4% | 7.1% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 156.67
(+65.77% Upside)
Earnings
Latest Release
Feb 23, 2026
EPS / Forecast
-0.61 / 0.09
Revenue / Forecast
121.00M / 120.55M
FAQ
What Is the GeneDx Holdings (WGS) Stock Price Today?
The GeneDx Holdings stock price today is 94.51.
What Stock Exchange Does GeneDx Holdings Trade On?
GeneDx Holdings is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for GeneDx Holdings?
The stock symbol for GeneDx Holdings is "WGS."
What Is the GeneDx Holdings Market Cap?
As of today, GeneDx Holdings market cap is 2.79B.
What Is GeneDx Holdings's Earnings Per Share (TTM)?
The GeneDx Holdings EPS (TTM) is -0.73.
When Is the Next GeneDx Holdings Earnings Date?
GeneDx Holdings will release its next earnings report on 13-05-2026.
From a Technical Analysis Perspective, Is WGS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has GeneDx Holdings Stock Split?
GeneDx Holdings has split 1 times.
How Many Employees Does GeneDx Holdings Have?
GeneDx Holdings has 1300 employees.
What is the current trading status of GeneDx Holdings (WGS)?
As of 10-03-2026, GeneDx Holdings (WGS) is trading at a price of 94.51, with a previous close of 88.11. The stock has fluctuated within a day range of 85.00 to 95.38, while its 52-week range spans from 55.17 to 170.87.
What Is GeneDx Holdings (WGS) Price Target According to Analysts?
The average 12-month price target for GeneDx Holdings is USD156.67, with a high estimate of USD177 and a low estimate of USD130. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +65.77% Upside potential.
What Is the WGS Premarket Price?
WGS's last pre-market stock price is 86.01. The pre-market share volume is 630.00, and the stock has decreased by -2.10, or -2.38%.
What Is the WGS After Hours Price?
WGS's last after hours stock price is 94.82, the stock has decreased by 0.31, or 0.33%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.